Association of cyp2c9*2 with bosentan-induced liver injury

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 6, 2013, Pages 678-686

  Markova, S M ^a   De Marco, T ^a   Bendjilali, N ^a   Kobashigawa, E A ^a   Mefford, J ^b   Sodhi, J ^c   Le, H ^c   Zhang, C ^c   Halladay, J ^c   Rettie, A E ^d   Khojasteh, C ^c   McGlothlin, D ^a   Wu, A H B ^b   Hsueh, W C ^a   Witte, J S ^b   Schwartz, J B ^a   Kroetz, D L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; CYTOCHROME P450 2C9; CYP2C9 PROTEIN, HUMAN; ENDOTHELIN RECEPTOR; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SULFONAMIDE; UNSPECIFIC MONOOXYGENASE; ENDOTHELIN RECEPTOR ANTAGONIST; GENETIC MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; CELL STRAIN HEK293; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; DRUG-INDUCED LIVER INJURY; HEK293 CELL LINE; HYPERTENSION, PULMONARY;

ALANINE TRANSAMINASE; ARYL HYDROCARBON HYDROXYLASES; ASPARTATE AMINOTRANSFERASES; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HEK293 CELLS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ENDOTHELIN; SULFONAMIDES; CYTOCHROME P-450 CYP2C9; ENDOTHELIN RECEPTOR ANTAGONISTS;

EID: 84887988640     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.143     Document Type: Article

References (50)

1. McLaughlin, V.V. et al.; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53, 1573-1619 (2009).
2. Tuder, R.M. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159, 1925-1932 (1999). (Pubitemid 29275065)
3. Christman, B.W. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327, 70-75 (1992).
4. Stewart, D.J., Levy, R.D., Cernacek, P. & Langleben, D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 114, 464-469 (1991).
5. Giaid, A. & Saleh, D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333, 214-221 (1995).
6. Thenappan, T., Shah, S.J., Rich, S. & Gomberg-Maitland, M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30, 1103-1110 (2007). (Pubitemid 351194756)
7. Dingemanse, J. & van Giersbergen, P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115 (2004). (Pubitemid 40013178)
8. Channick, R.N. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet 358, 1119-1123 (2001). (Pubitemid 32971843)
9. Rubin, L.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002). (Pubitemid 34984638)
10. Denton, C.P. et al.; TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 67, 1222-1228 (2008).
11. Treiber, A., Schneiter, R., H?sler, S. & Stieger, B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407 (2007). (Pubitemid 47121782)
12. Burgess, G., Hoogkamer, H., Collings, L. & Dingemanse, J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol. 64, 43-50 (2008).
13. van Giersbergen, P.L., Halabi, A. & Dingemanse, J. Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br. J. Clin. Pharmacol. 53, 589-595 (2002). (Pubitemid 34621784)
14. Dingemanse, J., van Giersbergen, P.L., Patat, A. & Nilsson, P.N. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir. Ther. (Lond.) 15, 157-163 (2010).
15. Fouassier, L. et al. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37, 184-191 (2002). (Pubitemid 34833079)
16. Fattinger, K. et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231 (2001). (Pubitemid 32382504)
17. Mano, Y., Usui, T. & Kamimura, H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance- associated protein 2. Biopharm. Drug Dispos. 28, 13-18 (2007). (Pubitemid 46165160)
18. Hartman, J.C., Brouwer, K., Mandagere, A., Melvin, L. & Gorczynski, R. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can. J. Physiol. Pharmacol. 88, 682-691 (2010).
19. Stieger, B., Meier, Y. & Meier, P.J. The bile salt export pump. Pflugers Arch. 453, 611-620 (2007). (Pubitemid 46192534)
20. Ho, R.H. et al. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet. Genomics 20, 45-57 (2010).
21. Lang, C. et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17, 47-60 (2007). (Pubitemid 46183791)
22. Pauli-Magnus, C. et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 14, 91-102 (2004). (Pubitemid 38253644)
23. Dixon, P.H. et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58, 537-544 (2009).
24. Humbert, M., Segal, E.S., Kiely, D.G., Carlsen, J., Schwierin, B. & Hoeper, M.M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338-344 (2007). (Pubitemid 47194187)
25. Daly, A.K., Aithal, G.P., Leathart, J.B., Swainsbury, R.A., Dang, T.S. & Day, C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272-281 (2007). (Pubitemid 46108755)
26. Choi, J.H. et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17, 403-415 (2007). (Pubitemid 46763385)
27. Nguyen, T.D. et al. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. (2012).
28. Hirouchi, M. et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 21, 742-748 (2004). (Pubitemid 39011294)
29. Haenisch, S., May, K., Wegner, D., Caliebe, A., Cascorbi, I. & Siegmund, W. Influence of genetic polymorphisms on intestinal expression and rifampicintype induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet. Genomics 18, 357-365 (2008). (Pubitemid 351367529)
30. Venitz, J., Zack, J., Gillies, H., Allard, M., Regnault, J. & Dufton, C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J. Clin. Pharmacol. 52, 1784-1805 (2012).
31. Lee, C.R., Goldstein, J.A. & Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263 (2002). (Pubitemid 34596790)
32. Cavallari, L.H., Shin, J. & Perera, M.A. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31, 1192-1207 (2011).
33. van der Weide, J., Steijns, L.S., van Weelden, M.J. & de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291 (2001). (Pubitemid 32537401)
34. Tang, C. et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11, 223-235 (2001). (Pubitemid 32319872)
35. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, J.A. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 43, 84-91 (2003). (Pubitemid 36015447)
36. Kirchheiner, J. & Brockm?ler, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005). (Pubitemid 40089477)
37. Chaudhry, A.S. et al. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J. Pharmacol. Exp. Ther. 332, 599-611 (2010).
38. Weiss, J., Theile, D., R?pell, M.A., Speck, T., Spalwisz, A. & Haefeli, W.E. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur. J. Pharmacol. 701, 168-175 (2013).
39. Belic, A. et al. Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches. Curr. Drug Metab. 10, 1066-1074 (2009).
40. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
41. Teichert, M. et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18, 3758-3768 (2009).
42. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
43. Srivastava, A., Srivastava, A., Srivastava, N., Choudhuri, G. & Mittal, B. Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India. Hepatol. Res. 41, 71-78 (2011).
44. Couvert, P., Chapman, M.J. & Carri? A. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterollowering therapy. Pharmacogenomics 12, 137-139 (2011).
45. Geng, F. et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin. Chim. Acta 413, 683-690 (2012).
46. Schwarz, U.I. et al. Identification of novel functional organic aniontransporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet. Genomics 21, 103-114 (2011).
47. Benichou, C., Danan, G. & Flahault, A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 46, 1331-1336 (1993). (Pubitemid 23333874)
48. Danan, G. & Benichou, C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323-1330 (1993). (Pubitemid 23333873)
49. Pai, R. et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci. 126, 446-456 (2012).
50. Tamraz, B. et al. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet. Genomics 23, 355-364 (2013).